A Model for the Assessment of Human Recombinant Interleukin 2 (RIL2) Coated Erythrocytes as a Delivery System for Immunotherapy

  • R. B. Moyes
  • J. R. DeLoach


A carrier system for IL2 is needed in order to circumvent the toxicity associated with high dose interleukin 2 (IL2) administration and its rapid clearance from circulation. Erythrocytes (RBC) coated with recombinant interleukin 2 (rIL2) provide a means of delivering IL2 into the system in a continuous, low dose manner which in turn maintains a low, potentially non-toxic, IL2 concentration. Murine RBC coated with rIL2 (RBC-rIL2) induce cytotoxicity (21–31%) upon cytotoxic testing of spleens cells stimulated in vivo. Using the murine Meth A sarcoma model, the effectiveness of this RBC-rIL2 vehicle is demonstrated in vivo by a 84% reduction in tumor size as compared to the soluble rIL2 treated mice. Moreover, the RBC-rIL2 vehicle is able to induce tumoricidal cytotoxicity with very low rIL2 concentrations (about 10,000 I.U. of rIL2 per mouse). These results indicate that rIL2 retains its biological activity when bound to the RBC and therefore could prove useful as a therapeutic delivery system for cancer treatment.


Spleen Cell Tumor Bearing Mouse Capillary Leak Syndrome CTLL Cell Interferon Gamma Production 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Anderson P.M., Katsanis E., Sencer S.F., Hasz D., Ochoa A.C., Bostrom B. (1992) Depot characteristics and bio-distribution of interleukin-2 liposomes: importance of route of administration. J Immunother 12, 19–31.PubMedCrossRefGoogle Scholar
  2. Anstee D.J., Gardner B., Spring F.A., Holmes C.H., Simpson K.L., Parsons S.F., Mallinson G., Yousaf S.M., Judson P.A. (1991) New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues. Immunol 74(2), 197–205.Google Scholar
  3. Cheever M.A., Thompson J.A., Kern D.E., Greenberg P.D. (1985) Interleukin-2 (IL2) administration in vivo: Influence of IL-2 route and timing on T cell growth. J Immunol 134, 3895–3900.PubMedGoogle Scholar
  4. Cheever M.A., Thompson J.A., Peace D.J., Greenberg P.D. (1986) Potential uses of interleukin 2 in cancer therapy. Immunobiol 172, 365–382.CrossRefGoogle Scholar
  5. Chiarantini L., Droleskey R., Magnani M., Kirch H., DeLoach J.R. (1992) Targeting of erythrocytes to cytotoxic T cells. In The use of resealed erythrocytes as carriers and bioreactors. Eds. M. Magnani and J.R. DeLoach. Plenum Press, New York, p.257.CrossRefGoogle Scholar
  6. Crum E.D., Kaplan D.R. (1991) In vivo activity of solid phase interleukin 2. Cancer Res 51, 875–879.PubMedGoogle Scholar
  7. DeLoach J.R., Tanger CT., Barton C. (1983) Hepatic pharmacokinetics of glutaraldehyde treated methotrexateloaded carrier erythrocytes in dogs. Res Exp Med 183, 167–175.CrossRefGoogle Scholar
  8. DeLoach J.R., Droleskey R. (1986) Survival of murine carrier erythrocytes injected via peritoneum. Comp Biochem Physiol 84A(3), 447–450.CrossRefGoogle Scholar
  9. DeLoach J.R., Andrews K., Sheffield C.L. (1988) Encapsulation of interleukin-2 in murine erythrocytes and subsequent deposition in mice receiving a subcutaneous injection. Biotech Appl Biochem 10, 183–190.Google Scholar
  10. Johnston T.P., Punjabi M.A., Froelich C.J. (1992) Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice. Pharm Res 9(3), 425–434.PubMedCrossRefGoogle Scholar
  11. Kalechman Y., Herman S., Gafter U., Sredni B. (1993) Enhancing effects of autologous erythrocytes on human or mouse cytokine secretion and IL-2R expression. Cell Immunol 148(1), 114–129.PubMedCrossRefGoogle Scholar
  12. Kaplan G., Cohn Z.A., Smith K.A. (1992) Rational immunotherapy with interleukin 2. Biotech 10, 157–162.CrossRefGoogle Scholar
  13. Lotze M.T., Chang A.E, Seipp C.A., Simpson C, Vetto J.T., Rosenberg S.A. (1986) High-dose recombinant interleukin-2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. JAMA 256, 3117–3124.PubMedCrossRefGoogle Scholar
  14. Mier J.W., Vachino G., Klempner M.S., Aronson F.R., Noring R., Smith S., Brandon E.R, Laird W., Atkins M.B. (1990) Inhibition of interleukin 2 induced tumor necrosis factor release by defect and differential suppression of interleukin 2 associated side effects. Blood 76, 1933–1940.PubMedGoogle Scholar
  15. Poste G., Kirsh R., Fogler W.E., Fidler I.J. (1979) Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. Cancer Res 39, 881–892.PubMedGoogle Scholar
  16. Ritz J., Schmidt R.E., Michon J., Hercend T., Schlossman S.F. (1988) Characterization of functional surface structures on human natural killer cells. Adv Immunol 42, 181–211.PubMedCrossRefGoogle Scholar
  17. Ropars C, Chassaigne M., Nicolau C. (1987) Resealed Erythrocyte as Carriers and Bioreactors. in Adv Biosciences vol. 67 Pergamon Press, Oxford.Google Scholar
  18. Rosenberg S.A., Lotze M.T., Muul L.M., Chang A.E., Avis F.P., Leitman S., Linehan W.M., Robertson C.N., Lee R.E., Rubin J.T., Seipp CA., Simpson CG., White D.E. (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high dose interleukin 2 alone. N Eng J Med 316, 889–905.CrossRefGoogle Scholar
  19. Sanders M.E., Makgoba M.W., June C.H., Young H.A., Shaw S. (1989) Enhanced responsiveness of human memory T cells to CD2 and CD3 receptor-mediated activation. EurJ Immunol 19(5), 803–808.CrossRefGoogle Scholar
  20. Sosman J.A., Weiss G.R., Margolin K.A., Aronson F.R., Sznol M., Atkins M.B., O’Boyle K., Fisher S.G., Mier J., Vachino G., Caliendo G. (1993) Phase I B clinical trial of anti-CD3 followed by high-dose bolus interleukin-2 in patients with metastatic melanoma and advanced renal cell carcinoma: clinical and immunological effects. J Clin Oncol 11, 1496–1505.PubMedGoogle Scholar
  21. Tamura K., Aso H., Nakamura T., Hemmi H., Ishida N. (1989) Evaluation of recombinant human tumor necrosis factor by scheduled intratumoral administration in mice bearing transplatable tumor. Tohoku J. Exp. Med, 157, 107–118.PubMedCrossRefGoogle Scholar
  22. Thrombe P.S., Deodhar S.D. (1984) Inhibition of liver metastases in murine colon adenocarcinoma by liposomes containing human c-reactive protein or crude lymphokine. Cancer Immunol Immunother 16, 145–150.Google Scholar
  23. Tuttle T.M., McCrady C.W., Inge T.H., Salour M., Bear H.D. (1992) ʳ-Interferon plays a key role in T cell induced tumor regression. Cancer Research 53, 833–839.Google Scholar
  24. Weigent D.A., Stanton G.J., Johnson H.M. (1983) Interleukin 2 enhances natural killer cell activity through induction of gamma interferon. Infect Imm 41, 992–997.32.Google Scholar

Copyright information

© Springer Science+Business Media New York 1997

Authors and Affiliations

  • R. B. Moyes
    • 1
  • J. R. DeLoach
    • 1
  1. 1.USDA-ARS-FAPRLCollege StationUSA

Personalised recommendations